Literature DB >> 21076601

Chemoendocrine Treatment Is Standard in Hormone Receptor-Positive Patients.

Volkmar Müller1.   

Abstract

Entities:  

Year:  2008        PMID： 21076601      PMCID： PMC2974976          DOI： 10.1159/000146066

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  6 in total

1.  Clinical application of the 70-gene profile: the MINDACT trial.

Authors:  Fatima Cardoso; Laura Van't Veer; Emiel Rutgers; Sherene Loi; Stella Mook; Martine J Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

3.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Authors:  F Jänicke; A Prechtl; C Thomssen; N Harbeck; C Meisner; M Untch; C G Sweep; H K Selbmann; H Graeff; M Schmitt
Journal:  J Natl Cancer Inst       Date:  2001-06-20       Impact factor: 13.506

4.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors:  Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

5.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; John Bryant; Stewart Anderson; James Dignam; Edwin R Fisher; Norman Wolmark
Journal:  Lancet       Date:  2004 Sep 4-10       Impact factor: 79.321

Review 6.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

Authors:  M Clarke; A S Coates; S C Darby; C Davies; R D Gelber; J Godwin; A Goldhirsch; R Gray; R Peto; K I Pritchard; W C Wood
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.